


Data Sheet

Product Name:	ETC-159
Cat. No.:	CS-5162
CAS No.:	1638250-96-0
Molecular Formula:	C ₁₉ H ₁₇ N ₇ O ₃
Molecular Weight:	391.38
Target:	Wnt
Pathway:	Stem Cell/Wnt
Solubility:	DMSO : ≥ 34 mg/mL (86.87 mM)



BIOLOGICAL ACTIVITY:

ETC-159 is a potent, orally available **PORCN** inhibitor. It inhibits β -catenin reporter activity with an **IC₅₀** of 2.9 nM. **IC₅₀ & Target:** IC₅₀: 2.9 nM (β -catenin)^[1] **In Vitro:** ETC-159 blocks the secretion and activity of all Wnts. ETC-159 has robust activity in multiple cancer models driven by high Wnt signaling. ETC-159 is highly efficacious in molecularly defined colorectal cancers (CRCs) with R-spondin translocations^[1] **In Vivo:** ETC-159 inhibits mouse PORCN with an IC₅₀ of 18.1 nM, whereas the IC₅₀ for *Xenopus* Porcn is approximately four fold higher (70 nM). ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. ETC-159 exhibits good oral pharmacokinetics in mice allowing preclinical evaluation via oral administration. After a single oral dose of 5 mg/kg, ETC-159 is rapidly absorbed into the blood with a **T_{max}** of ~0.5 h and oral bioavailability of 100%^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[1]HEK293 cells stably transfected with STF reporter and pPGK-WNT3A plasmid (STF3A cells) are treated with varying concentrations of compounds. For Wnt secretion, STF3A cells are treated with ETC-159 diluted in 1% fetal bovine serum-containing media^[1]. **Animal Administration:** ^[1]Mouse: For human xenograft models, patient-derived solid tissue fragments are subcutaneously implanted in BALB/c nude mice. All groups are matched for tumor size with equal variance before treatment. ETC-159 formulated in 50% PEG400 (vol/vol) in water is administered by oral gavage at a dosing volume of 10 μ L/g body weight^[1].

References:

[1]. Madan B, et al. Wnt addiction of genetically defined cancers reversed by PORCN inhibition. *Oncogene*. 2015 Aug 10. doi: 10.1038/onc.2015.280.

CAIndexNames:

7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-

SMILES:

O=C(NC1=CC=C(C2=CC=CC=C2)N=N1)CN3C=NC4=C3C(N(C)C(N4C)=O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA